Table 3.
Clinical and serological changes 3 months after rituximab therapy
| Group A |
Group B |
Compare group A with group B |
p-value†of month 3 values | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline | After 3 months | p-value⁎ | Baseline | After 3 months | p-value⁎ | p-value† of baseline values | ||
| Prednisolone dose (mg) | 46.83 ± 19.44 (0-80) | 9.73 ± 5.95 (0-30) | < .001 | 20.13 ± 17.53 (0-80) | 8.16 ± 5.30 (0-25) | < .001 | < 0.001 | .23 |
| Mucosal PDAI | 13.99 ± 14.47 | 1.40 ± 3.27 | < .001 | 12.79 ± 15.05 | 1.526 ± 2.97 | < .001 | 0.726 | .867 |
| Cutaneous PDAI | 10.28 ± 13.86 | 0.14 ± 0.54 | < .001 | 9.40 ± 9.43 | 0.77 ± 2.14 | < .001 | 0.750 | .083 |
| Skin PDAI | 8.33 ± 11.76 | 0.135 ± 0.53 | < .001 | 6.29 ± 7.65 | 0.771 ± 2.14 | < .001 | 0.377 | .083 |
| Scalp PDAI | 1.95 ± 3.14 | 0.027 ± 0.16 | .001 | 3.11 ± 3.88 | 1.43 ± 3.41 | .003 | 0.158 | .016 |
| Total PDAI | 24.25 ± 19.88 | 1.57 ± 3.25 | < .001 | 22.171 ± 17.98 | 3.72 ± 5.4 | < .001 | 0.636 | .042 |
| Total anti-Dsg1 Ab (U/ml) | 62.80 ± 80.98 | 3.20 ± 4.42 | < .001 | 100.65 ± 106.24 | 27.28 ± 57.33 | < .001 | 0.88 | .014 |
| Pathogenic anti-Dsg1 Ab (U/ml) |
58.46 ± 81.00 | 2.12 ± 4.23 | < .001 | 94.37 ± 105.84 | 25.24 ± 56.34 | < .001 | 0.104 | .016 |
| Non-pathogenic anti-Dsg1 Ab (U/ml) | 4.34 ± 11.16 | 1.08 ± 0.28 | < .001 | 4.26 ± 8.67 | 2.03 ± 3.03 | < .001 | 0.974 | .062 |
| Total anti-Dsg3 Ab (U/ml) | 180.39 ± 100.81 | 45.99 ± 65.35 | < .001 | 171.89 ± 89.10 | 88.23 ± 83.45 | < .001 | 0.700 | .017 |
| Pathogenic anti-Dsg3 Ab (U/ml) | 164.45 ± 91.41 | 43.71 ± 63.93 | < .001 | 157.24 ± 80.07 | 82.54 ± 77.87 | < .001 | 0.717 | .021 |
| Non-pathogenic anti-Dsg3 Ab (U/ml) | 15.94 ± 19.99 | 2.28 ± 2.24 | < .001 | 14.65 ± 19.18 | 5.69 ± 8.37 | .001 | 0.777 | .020 |
Ab, antibody; Dsg, desmoglein; PDAI, Pemphigus Disease Area Index.
⁎
Paired t test.
†
Independent t test.